Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.
Privitera G, Bezzio C, Figlioli G, D'Amico F, Mendes J, Varca S, Zingone F, Rodriguez-Lago I, Onali S, Caprioli FA, Chaparro M, Barreiro-de-Acosta M, Karmiris K, Degabli NT, Dar L, Pastorelli L, Gutiérrez A, Orlando A, Zabana Y, Saibeni S, Piovani D, Savarino EV, Pugliese D, Magro F, Danese S, Armuzzi A; PODIUM Study Group.
Privitera G, et al.
Clin Gastroenterol Hepatol. 2026 Jan 29:S1542-3565(26)00045-5. doi: 10.1016/j.cgh.2026.01.017. Online ahead of print.
Clin Gastroenterol Hepatol. 2026.
PMID: 41616901
Free article.